Randomized Phase II Study of Carboplatin-Paclitaxel or Gemcitabine-Vinorelbine in Patients With Advanced Nonsmall Cell Lung Cancer and a Performance Status of 2-Reference-Cited by-同舟云学术

Randomized Phase II Study of Carboplatin-Paclitaxel or Gemcitabine-Vinorelbine in Patients With Advanced Nonsmall Cell Lung Cancer and a Performance Status of 2

Published:2012-02 Issue:1 Volume:35 Page:58-63
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Saito Hiroshi,Nakagawa Kazuhiko,Takeda Koji,Iwamoto Yasuo,Ando Masahiko,Maeda Masao,Katakami Nobuyuki,Nakano Takashi,Kurata Takayasu,Fukuoka Masahiro

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference28 articles.

1. Chemotherapy versus supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature.;Marino;Chest,1994

2. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.;Bonomi;J Clin Oncol,2000

3. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial.;Kelly;J Clin Oncol,2001

4. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.;Kosmidis;J Clin Oncol,2002

5. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.;Schiller;N Engl J Med,2002

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status;Cochrane Database of Systematic Reviews;2023-07-07

2. Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?;Cancers;2022-10-05

3. Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial;Investigational New Drugs;2020-05-18

4. Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer;Anticancer Research;2019-03

5. Chemotherapy for advanced non-small cell lung cancer in the elderly population;Cochrane Database of Systematic Reviews;2015-10-20